Imaging Test Targeting DLL3 for Small Cell Lung Cancer Patients
Tests a DLL3-targeted PET scan in adults with suspected or confirmed small cell lung cancer.
Key facts
- Who runs it
- The First Affiliated Hospital of Xiamen University
- Where
- Xiamen, ChinaSee the site
- Trial code
- Registry title
- DLL3-Targeted PET/CT in Small Cell Lung Cancer
- Status
- Recruiting
- People taking part
- 20 people, planned
- Started
- 9 May 2026
- Expected to end
- 31 May 2028
- Type of study
- Interventional
- Treatments tested
- conventional imaging (CT, MRI or 18F-FDG PET/CT), DLL3-targeted PET/CT
- Record updated
- 1 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with suspected, newly diagnosed or previously treated small cell lung cancer, to test a DLL3-targeted PET/CT scan against usual imaging.
- Age
- 18 Years to 80 Years
- Sex
- All sexes can join.
- Disease stage
- Suspected, newly diagnosed, or previously treated small cell lung cancer; imaging findings and a pathology report may support this.
- Earlier treatment
- Previously treated small cell lung cancer is allowed; no specific prior treatment is required.
- Biomarker or test result
- Serum ProGRP or NSE level at least 3 times the upper limit of normal.
Main reasons for not taking part
- Cannot or will not give written informed consent
- Cannot complete PET/CT imaging
- Expected life expectancy of 3 months or less, as judged by the investigator
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Adult patients (aged 18 years or older)
- Patients with suspected, newly diagnosed, and previously treated small cell lung cancer(supporting evidence may include imaging findings and pathology report)
- Serum ProGRP or NSE level ≥ 3 times the upper limit of normal
- Patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee
- Estimated life expectancy of more than 3 months, as assessed by the investigator, and ability to comply with study procedures and scheduled visits
Who cannot take part
- The inability or unwillingness of the research participant or legal representative to provide written informed consent
- Inability to complete PET/CT imaging
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Where in China
- The First Affiliated hospital of Xiamen UniversityXiamen, ChinaContact: Liang ZhaoTaking people
About the trial
What the trial wants to find out
The objective of the study is to evaluate the diagnostic value of DLL3-targeted PET/CT in patients with suspected or histologically confirmed small cell lung cancer, and to compare with conventional imaging modalities.
The group in the trial
- DLL3-targeted PET/CTTreatment being tested
Each subject receives a single intravenous injection of DLL3-targeted probe and undergoes PET/CT imaging within the specified time.
Treatment: conventional imaging (CT, MRI or 18F-FDG PET/CT), DLL3-targeted PET/CT
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Delta-like Protein 3 (DLL3)- Targeted PET Imaging in Small Cell Lung Cancer
- Plain-language title
- Imaging Test Targeting DLL3 for Small Cell Lung Cancer PatientsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT07677787, who can take part
- Record updated
- 1 July 2026